Ratings Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Market Closed - BOERSE MUENCHEN Other stock markets 03:44:14 2024-06-28 pm EDT			5-day change	1st Jan Change
4.52 ^EUR	-3.00%		+7.11%	-14.72%

Jun. 04	Akeso Expands Territory of License Agreement for Lung Cancer Drug	MT
Jun. 03	Summit Therapeutics Inc. Expands License Territories for Ivonescimab	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AKESO, INC.	-14.72%	4.19B	-
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B	B+
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B	B+
ARGENX SE	+18.95%	26.02B	B
BIONTECH SE	-23.86%	19.39B	B+
GENMAB A/S	-19.03%	15.91B	A-
BEIGENE, LTD.	-20.90%	15.09B	B
WUXI APPTEC CO., LTD.	-46.14%	15.06B	A-
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B	C+
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes